Literature DB >> 11257240

Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer's disease.

S Rasmuson1, R Andrew, B Näsman, J R Seckl, B R Walker, T Olsson.   

Abstract

BACKGROUND: Abnormalities at several levels of the hypothalamic-pituitary-adrenal axis, which may promote glucocorticoid dependent neurodegeneration, have been reported in patients with Alzheimer's disease. In this study we have explored the possibility that peripheral cortisol metabolism is enhanced and glucocorticoid production is increased compensatory in patients with mild to moderate Alzheimer's disease.
METHODS: Urinary excretion of cortisol and its principal conjugated metabolites was studied in ten women with mild to moderate Alzheimer's disease, seven healthy elderly women and seven young women.
RESULTS: There was an age-related fall in glucocorticoid production (median, 2009 [range 1828--4201] vs. 9315 [range 3613--16,244] microg/24 hours in elderly vs. young control subjects). A-ring metabolism (i.e., the irreversible inactivation of cortisol by 5 alpha- and 5 beta-reductases) was reduced in old age. However, patients with Alzheimer's disease showed persistence of cortisol metabolite excretion. Glucocorticoid production was significantly increased in patients with Alzheimer's disease versus healthy elderly control subjects (median, 7269 [range 6005-15,335] vs. 2009 [range 1828--4201] microg/24 hours), and patients with Alzheimer's disease had increased A-ring reduction of cortisol.
CONCLUSIONS: An increased glucocorticoid production is an early feature of Alzheimer's disease and may be secondary to enhanced metabolic clearance of cortisol by A-ring reduction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257240     DOI: 10.1016/s0006-3223(00)01015-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  32 in total

1.  Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer's disease.

Authors:  Fabien Lanté; Magda Chafai; Elisabeth Fabienne Raymond; Ana Rita Salgueiro Pereira; Xavier Mouska; Scherazad Kootar; Jacques Barik; Ingrid Bethus; Hélène Marie
Journal:  Neuropsychopharmacology       Date:  2015-01-27       Impact factor: 7.853

2.  The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease.

Authors:  Nunzio Pomara; Raymundo T Hernando; Corazon B de la Pena; John J Sidtis; Thomas B Cooper; Steven Ferris
Journal:  Neurochem Res       Date:  2006-05-23       Impact factor: 3.996

3.  Human tau may modify glucocorticoids-mediated regulation of cAMP-dependent kinase and phosphorylated cAMP response element binding protein.

Authors:  Yudong Liu; Ying Su; Shenggang Sun; Tao Wang; Xian Qiao; Hui Li; Xiaoqin Run; Zhihou Liang
Journal:  Neurochem Res       Date:  2012-05       Impact factor: 3.996

4.  3xTgAD mice exhibit altered behavior and elevated Aβ after chronic mild social stress.

Authors:  Sarah M Rothman; Nathan Herdener; Simonetta Camandola; Sarah J Texel; Mohamed R Mughal; Wei-Na Cong; Bronwen Martin; Mark P Mattson
Journal:  Neurobiol Aging       Date:  2011-08-19       Impact factor: 4.673

5.  Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Aβ and pTau in a mouse model of Alzheimer's disease.

Authors:  Sarah M Rothman; Nathan Herdener; Kathryn A Frankola; Mohamed R Mughal; Mark P Mattson
Journal:  Brain Res       Date:  2013-07-13       Impact factor: 3.252

6.  Immunoreactivities and levels of mineralocorticoid and glucocorticoid receptors in the hippocampal CA1 region and dentate gyrus of adult and aged dogs.

Authors:  Jung Hoon Choi; In Koo Hwang; Choong Hyun Lee; Dae Won Chung; Ki-Yeon Yoo; Hua Li; Moo-Ho Won; Je Kyung Seong; Yeo Sung Yoon; In Se Lee
Journal:  Neurochem Res       Date:  2007-11-06       Impact factor: 3.996

7.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

Review 8.  Estrogen and Alzheimer's disease: the story so far.

Authors:  Brenna Cholerton; Carey E Gleason; Laura D Baker; Sanjay Asthana
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 9.  Adverse stress, hippocampal networks, and Alzheimer's disease.

Authors:  Sarah M Rothman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2009-11-27       Impact factor: 3.843

Review 10.  Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology.

Authors:  Makoto Ishii; Costantino Iadecola
Journal:  Cell Metab       Date:  2015-09-10       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.